Description: Reliably optimizing a new treatment in humans is a critical first step in clinical evaluation since choosing a suboptimal dose or schedule may lead to failure in later trials. At the same time, if promising preclinical results do not translate into a real treatment advance, it is important to determine this quickly and terminate the clinical evaluation process to avoid wasting resources. Bayesian Designs for Phase I–II Clinical Trials describes how phase I–II designs can serve as a bridge or protective barrier between preclinical studies and large confirmatory clinical trials. It illustrates many of the severe drawbacks with conventional methods used for early-phase clinical trials and presents numerous Bayesian designs for human clinical trials of new experimental treatment regimes. Written by research leaders from the University of Texas MD Anderson Cancer Center, this book shows how Bayesian designs for early-phase clinical trials can explore, refine, and optimize new experimental treatments. It emphasizes the importance of basing decisions on both efficacy and toxicity.
Price: 56.09 USD
Location: Gloucester
End Time: 2024-11-05T01:57:18.000Z
Shipping Cost: 0 USD
Product Images
Item Specifics
Return shipping will be paid by: Buyer
All returns accepted: Returns Accepted
Item must be returned within: 60 Days
Refund will be given as: Money Back
Return policy details:
EAN: 9781032242644
UPC: 9781032242644
ISBN: 9781032242644
MPN: N/A
Book Title: Bayesian Designs for Phase I-II Clinical Trials (C
Item Height: 2.72 cm
Number of Pages: 324 Pages
Publication Name: Bayesian Designs for Phase III Clinical Trials
Language: English
Publisher: CRC Press LLC
Subject: Biostatistics, Probability & Statistics / General, General, Pharmacology
Publication Year: 2021
Type: Textbook
Item Weight: 21.2 Oz
Item Length: 9.2 in
Author: Hoang Q. Nguyen, Peter F. Thall, Ying Yuan
Subject Area: Mathematics, Medical
Series: Chapman and Hall/Crc Biostatistics Ser.
Item Width: 6.1 in
Format: Trade Paperback
